<DOC>
	<DOC>NCT02104167</DOC>
	<brief_summary>The purpose of this combined retrospective and prospective clinical study is to examine safety and efficacy of the ROI-C® anterior cervical interbody fusion device with VerteBRIDGE® plating to treat single level degenerative disc disease between C2 and T1 in the short term, with a focus on fusion rates.</brief_summary>
	<brief_title>Retrospective/Prospective Data Collection on the LDR ROIC Interbody Fusion Device With VerteBRIDGE Plating</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Subject must have degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one level between C2 and T1. The subject can have the ROIC device at only one level. Autograft must have been used with the ROIC device. Subject should have had a minimum of 6 (six) weeks of nonoperative treatment prior to surgery. Subject must be at least 21 years of age at the time of surgery No BMP was used in the interbody cage Subject was a prisoner at the time of surgery Subject was pregnant at the time of surgery Subject had an active infection or sepsis at the time of surgery</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>DDD</keyword>
	<keyword>degenerative disc disease</keyword>
	<keyword>cervical spine</keyword>
	<keyword>fusion rate</keyword>
</DOC>